Comparative effectiveness of drugs for chronic obstructive pulmonary disease

Drugs of Today

Volumn 48, Issue 12, 2012, Pages 785-794

  Cazzola, Mario ^a   Segreti, A ^a   Rogliani, P ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Bronchodilators; Chronic obstructive pulmonary disease; Guidelines; Inhaled corticosteroids; Personalized therapy; Phenotypes

Indexed keywords

ACLIDINIUM BROMIDE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; INDACATEROL; IPRATROPIUM BROMIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; SALMETEROL; TIOTROPIUM BROMIDE;

BRONCHODILATATION; CARDIOVASCULAR RISK; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; COMORBIDITY; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; LONG TERM CARE; LUNG FUNCTION; META ANALYSIS (TOPIC); MONOTHERAPY; MORTALITY; PATIENT CARE; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; REVIEW; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME;

COMPARATIVE EFFECTIVENESS RESEARCH; GUIDELINES AS TOPIC; HUMANS; PHYSICIANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84871589418     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48.12.1860770     Document Type: Review

References (54)

1. D'Avolio, L.W., Farwell, W.R., Fiore, L.D. Comparative effectiveness research and medical informatics. Am J Med 2010, 123(12, Suppl. 1): e32-7.
2. Kupersmith, J., Ommaya, A.K. The past, present, and future of comparative effectiveness research in the US Department of Veterans Affairs. Am J Med 2010, 123 (12, Suppl. 1): e3-7.
3. Conway, P.H., Clancy, C. Comparative-effectiveness research - implications of the Federal Coordinating Council's report. N Engl J Med 2009, 361(4): 328-30.
4. Witt, C.M., Manheimer, E., Hammerschlag, R., Lüdtke, R., Lao, L., Tunis, S.R., Berman, B.M. How well do randomized trials inform decision making: systematic review using comparative effectiveness research measures on acupuncture for back pain. PLoS ONE 2012, 7(2): e32399.
5. Concato, J., Lawler, E.V., Lew, R.A., Gaziano, J.M., Aslan, M., Huang, G.D. Observational methods in comparative effectiveness research. Am J Med 2010, 123(12, Suppl. 1): e16-23.
6. Cox, E., Martin, B.C., Van Staa, T., Garbe, E., Siebert, U., Johnson, M.L. Good research practices for comparative effectiveness research: approaches to mitigate bias and confounding in the design of nonrandomized studies of treatment effects using secondary data sources: The International Society for Pharmacoeconomics and Outcomes Research Good Research Practices for Retrospective Database Analyses Task Force Report - Part II. Value Health 2009, 12(8): 1053-61.
7. Krishnan, J.A., Mularski, R.A. Acting on comparative effectiveness research in COPD. JAMA 2010, 303(23): 2409-10.
8. Lieu, T.A., Au, D., Krishnan, J.A. et al. Comparative effectiveness research in lung diseases and sleep disorders: recommendations from the NHLBI workshop. Am J Respir Crit Care Med 2011, 184(7): 848-56.
9. Krishnan, J.A., Schatz, M., Apter, A.J. A call for action: comparative effectiveness research in asthma. J Allergy Clin Immunol 2011, 127(1): 123-7.
10. Puhan, M.A., Bachmann, L.M., Kleijnen, J., Ter Riet, G., Kessels, A.G. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Med 2009, 7: 2.
11. Caldwell, D.M., Ades, A.E., Higgins, J.P. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005, 331 (7521): 897-900. (Pubitemid 41502718)
12. Lumley, T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002, 21 (16): 2313-24.
13. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD. 2011 update . http://www.goldcopd.org. Accessed July 2, 2012.
14. National Institute for Health and Clinical Excellence. National Clinical Guideline Centre. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults in primary and secondary care. http://guidance.nice.org.uk/CG101/Guidance/pdf/English. Accessed July 2, 2012.
15. Travers, J., Marsh, S., Caldwell, B. et al. External validity of randomized controlled trials in COPD. Respir Med 2007, 101:1313-20. (Pubitemid 46667661)
16. Krishnan, A. Con: comparative effectiveness research. More than dollars and cents. Am J Respir Crit Care Med 2011, 183(8): 975-6.
17. Jochmann, A., Scherr, A., Jochmann, D.C. et al. Impact of adherence to the GOLD guidelines on symptom prevalence, lung function decline and exacerbation rate in the Swiss COPD cohort. Swiss Med Wkly 2012, 142: w13567.
18. Pickard, A.S., Lee, T.A., Solem, C.T., Joo, M.J., Schumock, G.T., Krishnan, J.A. Prioritizing comparative-effectiveness research topics via stakeholder involvement: an application in COPD. Clin Pharmacol Ther 2011, 90(6): 888-92.
19. Wedzicha, J.A. Choice of bronchodilator therapy for patients with COPD. N Engl J Med 2011, 364(12): 1167-8.
20. 2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 163(5): 1087-92.
21. Dahl, R., Greefhorst, L.A., Nowak, D. et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 164(5): 778-84. (Pubitemid 32881913)
22. Donohue, J.F., van Noord, J.A., Bateman, E.D. et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002, 122(1): 47-55. (Pubitemid 34754142)
23. Vogelmeier, C., Hederer, B., Glaab, T. et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011, 364(12): 1093-103.
24. 2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease. Ther Adv Respir Dis 2011, 5(5): 345-57.
25. Singh, D., Magnussen, H., Kirsten, A. et al. A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients. Pulm Pharmacol Ther 2012, 25(3): 248-53.
26. Fuhr, R., Magnussen, H., Sarem, K. et al. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Chest 2012, 141(3): 745-52.
27. Cazzola, M., Page, C.P., Calzetta, L., Matera, M.G. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012, 64(3): 450-504.
28. Cazzola, M., Rogliani, P., Segreti, A., Matera, M.G. An update on bronchodilators in phase I and II clinical trials. Expert Opin Investig Drugs 2012, 21(10): 1489-501.
29. Rodrigo, G.J., Neffen, H. Comparison of indacaterol with tiotropium or twice-daily long-acting beta-agonists for stable COPD: a systematic review. Chest 2012, Advance publication.
30. Price, D., Gray, A., Gale, R. et al. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD. Respir Med 2011, 105(11): 1635-47.
31. Gershon, A., Croxford, R., To, T., Stanbrook, M.B., Upshur, R., Sanchez-Romeu, P., Stukel, T. Comparison of inhaled long-acting β-agonist and anticholinergic effectiveness in older patients with chronic obstructive pulmonary disease: a cohort study. Ann Intern Med 2011, 154(9): 583-92.
32. Dalal, A.A., Roberts, M.H., Petersen, H.V., Blanchette, C.M., Mapel, D.W. Comparative cost-effectiveness of a fluticasone-propionate/salmeterol combination versus anticholinergics as initial maintenance therapy for chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2010, 6: 13-22.
33. Celli, B. What is the best pharmacological treatment to prevent exacerbation of chronic obstructive pulmonary disease? Pol Arch Med Wewn 2008, 118(4): 172-4. (Pubitemid 351613054)
34. van der Molen, T., Cazzola, M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J 2012, 21(1): 101-8.
35. Aaron, S.D., Vandemheen, K.L., Fergusson, D. et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007, 146(8): 545-55. (Pubitemid 351650535)
36. Vogelmeier, C., Kardos, P., Harari, S., Gans, S.J., Stenglein, S., Thirlwell, J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008, 102(11): 1511-20.
37. Cazzola, M., MacNee, W., Martinez, F.J. et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008, 31(2): 416-69.
38. Cazzola, M., Molimard, M. The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010, 23(4): 257-67.
39. Mahler, D.A., D'Urzo, A., Bateman, E.D. et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012, 67(9): 781-8.
40. Tashkin, D.P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S., Decramer, M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008, 359(15): 1543-54.
41. Telenga, E.D., Kerstjens, H.A., Postma, D.S., Ten Hacken, N.H., van den Berge, M. Inhaled corticosteroids in chronic obstructive pulmonary disease: a review. Expert Opin Pharmacother 2010, 11(3): 405-21.
42. Calverley, P.M.A., Anderson, J.A., Celli, B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356(8): 775-89. (Pubitemid 46294610)
43. Short, P.M., Williamson, P.A., Elder, D.H., Lipworth, S.I., Schembri, S., Lipworth, B.J. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPD. Chest 2012, 141(1): 81-6.
44. Rodrigo, G.J., Plaza, V., Castro-Rodríguez, J.A. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. Pulm Pharmacol Ther 2012, 25(1): 40-7.
45. Salama, R.O., Young, P.M., Rogueda, P., Lallement, A., Iliev, I., Traini, D. Advances in drug delivery: Is triple therapy the future for the treatment of chronic obstructive pulmonary disease? Expert Opin Pharmacother 2011, 12(12): 1913-32.
46. Najafzadeh, M., Marra, C.A., Sadatsafavi, M. et al. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD. Thorax 2008, 63(11): 962-7.
47. Celli, B.R. Chronic obstructive pulmonary disease: from unjustified nihilism to evidence-based optimism. Proc Am Thorac Soc 2006, 3(1): 58-65.
48. Matera, M.G., Cazzola, M. Treatment of COPD: no longer nihilism, but there is still an urgent need for new therapies. Curr Opin Pharmacol 2012, 12(3): 225-8.
49. Han, M.K., Agusti, A., Calverley, P.M. et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010, 182(5): 598-604.
50. Fingleton, J., Weatherall, M., Beasley, R. Towards individualised treatment in COPD. Thorax 2011, 66(5): 363-4.
51. Vestbo, J., Edwards, L.D., Scanlon, P.D. et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011, 365(13): 1184-92.
52. Cazzola, M., Bettoncelli, G., Sessa, E., Cricelli, C., Biscione, G. Prevalence of comorbidities in patients with chronic obstructive pulmonary disease. Respiration 2010, 80(2): 112-9.
53. Matera, M.G., Calzetta, L., Rinaldi, B., Cazzola, M. Treatment of COPD: moving beyond the lungs. Curr Opin Pharmacol 2012, 12(3): 315-22.
54. Mularski, R.A., McBurnie, M.A., Lindenauer, P.K. et al. Comparative effectiveness research in chronic obstructive pulmonary disease. J Compar Effect Res 2012, 1(1): 71-82.